Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Honghua Ruyi Pills (HHRYW), also known as 'Safflower Wishful Pill' or 'Guge Sangpei' in Tibetan, is a traditional Tibetan medicine oral formulation developed and marketed by Tibet Cheezheng Tibetan Medicine (Gansu Cheezheng). The formulation is a modification of the classical '25-ingredient Podophyllum Pill' and contains 25 key ingredients, most of which are native to the Qinghai-Tibet Plateau. It is an approved traditional herbal medicine primarily indicated for various gynecological conditions, including endometriosis-associated dysmenorrhea, pelvic inflammatory disease pain, and menstruation disorders. The drug demonstrates anti-inflammatory and analgesic properties, effectively alleviating chills and pain associated with menstrual irregularities. While its clinical efficacy is documented, its specific molecular targets and pharmacological mechanisms have not been fully characterized in Western pharmacological terms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Honghua Ruyi Pills.